GlassScriptPhysician profile
Tamera Kajy
NPI 1801516141
$6,385.20
in general payments reported to CMS, 2019-2025
22 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,596 · 2024: $2,961 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,385.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,385.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,884.04 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,738.45 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $572.10 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $319.56 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $278.26 | 2023-2025 | Linzess |
| Gilead Sciences, INC. | $230.57 | 2023-2024 | Vemlidy |
| Regeneron Healthcare Solutions, INC. | $213.27 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $162.55 | 2023-2025 | Ibsrela |
| Celgene Corporation | $159.88 | 2023-2024 | Zeposia |
| Qol Medical, LLC | $148.95 | 2023-2025 | Sucraid, Sucraid |
| Celltrion USA INC. | $145.53 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $88.65 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $88.62 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $85.70 | 2025 | Voquezna |
| Genzyme Corporation | $51.47 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $50.43 | 2023 | Sutab, Suflave |
| Janssen Biotech, INC. | $40.88 | 2025 | Simponi Aria, Stelara, Tremfya |
| Organon LLC | $37.84 | 2023 | Hadlima |
| Madrigal Pharmaceuticals | $27.92 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $24.86 | 2024 | Bylvay |
| Intercept Pharmaceuticals, INC. | $20.59 | 2023 | Ocaliva |
| Redhill Biopharma INC. | $15.08 | 2023 | Talicia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Kajy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.